Introduction
============

All European Union (EU) countries and the United Kingdom (UK) recommend seasonal influenza vaccine for older adults and those at increased risk of influenza complications and severe disease, as well as for patients with chronic conditions \[[@r1]\]. In addition, universal childhood influenza is available in some countries in the World Health Organization (WHO) European Region, and was introduced incrementally in the UK in 2013/14 \[[@r2]\].

The 2019/20 northern hemisphere influenza season WHO trivalent influenza vaccine strains recommendations were for an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/Kansas/14/2017(H3N2)-like virus and a B/Colorado/06/2017-like virus (B/Victoria lineage) \[[@r3]\]. Quadrivalent vaccines were recommended to also include a B/Phuket/3073/2013-like virus (B/Yamagata lineage) \[[@r4]\].

The 2019/20 influenza season started early in most countries of the WHO European Region, with influenza A(H1N1)pdm09 and A(H3N2) virus subtypes, as well as influenza B circulating throughout the region, although predominantly influenza A overall (69%) \[[@r5]\]. Despite this, some countries reported dominance of influenza B, with a few reporting co-dominance \[[@r5]\].

The I-MOVE (Influenza -- Monitoring Vaccine Effectiveness in Europe) network has measured influenza vaccine effectiveness (VE) annually since 2008/09, with its partners including Denmark, Spain, the UK and many EU countries measuring VE through the I-MOVE multicentre studies. We summarise interim influenza VE estimates for the 2019/20 season from six studies (four single-country and two multi-country), with out- and in-patient (hospital) settings, in order to provide information for measures of influenza prevention and control for the remaining season. Results presented here also helped to inform the February 2020 WHO Vaccine Strain Selection Committee.

Methods
=======

Study setting
-------------

The four primary care (PC) studies were conducted in Denmark (DK-PC), Spain (ES-PC), the UK (UK-PC) and through the EU I-MOVE multi-country network (EU-PC; eight of nine participating countries in this network having available data for interim analysis). The two hospital setting (H) studies were in Denmark (DK-H) and through the EU I-MOVE multi-country network (EU-H; two of 11 participating countries in this network having available data for interim analysis) ([Figure 1](#f1){ref-type="fig"}). In total, 10 countries contributed data to the interim influenza vaccine effectiveness results presented in this article.
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Study design
------------

The methods for all six studies have already been described \[[@r6]-[@r10]\]. The test-negative design \[[@r11]\] was used in all studies, although some studies varied in their patient selection and/or data collection ([Table 1](#t1){ref-type="table"}). Briefly, patients presenting to participating primary care settings with symptoms of influenza-like illness (ILI) or acute respiratory infection (ARI) were swabbed. For the hospital setting swabs were taken from those with symptoms of severe ARI (SARI). Three studies used an exhaustive or systematic selection of patients to swab (EU-H, ES-PC and EU-PC), while physicians\' discretion was used to select patients for swabbing in the others (DK-H, DK-PC and UK-PC). Samples were tested by reverse transcription (RT)-PCR for generic influenza virus detection, type A subtyping and type B lineage determination. Cases were defined as patients with positive results by influenza virus (sub)type. Controls were defined as those with negative results.

###### Summary of methods for the six European interim influenza vaccine effectiveness studies, influenza season 2019/20 (n  = 31,537)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study characteristics                                Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study period                                         1 October 2019--29 January 2020                                                                                            28 October 2019--26 January 2020                                                                                          30 September 2019--25 January 2020                                                                                                                                                                    1 October 2019--12 January 2020                                                                                                                   1 October 2019--29 January 2020                                                                                            2 December 2019--26 January 2020

  Setting                                              Primary care                                                                                                               Primary care                                                                                                              Primary care                                                                                                                                                                                          Primary care                                                                                                                                      Hospital                                                                                                                   Hospital

  Location                                             Denmark                                                                                                                    Spain: Sentinel networks in 16 of 19 regions                                                                              France, Germany, Ireland, the Netherlands, Portugal, Romania, Spain and Sweden                                                                                                                        England, Scotland, Northern Ireland and Wales                                                                                                     Denmark                                                                                                                    Spain: six hospitals in three regions; Romania: three hospitals

  Study design                                         TND                                                                                                                        TND                                                                                                                       TND                                                                                                                                                                                                   TND                                                                                                                                               TND                                                                                                                        TND

  Data source                                          Data linkage of Danish Microbiology Database, the Danish Vaccination Register and the Danish National Discharge Register   Sentinel physicians and laboratory^a^                                                                                     Sentinel physicians and laboratory^a^                                                                                                                                                                 Sentinel physicians and laboratory                                                                                                                Data linkage of Danish Microbiology Database, the Danish Vaccination Register and the Danish National Discharge Register   Hospital charts, vaccine registers, interviews with GPs, laboratory

  Age groups of study population                       ≥ 6 months                                                                                                                 ≥ 6 months                                                                                                                All ages^b^                                                                                                                                                                                           All ages                                                                                                                                          ≥ 6 months                                                                                                                 ≥ 65 years

  Case definition                                      Sudden onset of symptoms with fever, myalgia and respiratory symptoms                                                      EU ILI^c^                                                                                                                 EU ILI^c^                                                                                                                                                                                             ILI: Patient presenting in primary care with an acute respiratory illness with physician diagnosed fever, and with onset in the previous 7 days   ARI: Sudden onset of symptoms with fever, myalgia and respiratory symptoms among hospitalised patients                     EU SARI^d^

  Selection of patients                                At physician's judgement                                                                                                   Systematic                                                                                                                Systematic                                                                                                                                                                                            At physician's judgement                                                                                                                          At physician's judgement                                                                                                   Exhaustive

  Vaccine types used nationally or in the study^e,f^   In the study: 99.5% QIV, 0.5% cell-propagated QIV                                                                          In Spain: 81.8% TIV, 10.3% QIV and 7.8% cell-propagated QIV                                                               In the study among controls:\                                                                                                                                                                         In the study among controls^g^: 7% LAIV4; 12% cell-propagated QIV, 14% QIV, 22% adjuvanted TIV; 44% unknown                                       In the study: 99.5% QIV, 0.5% cell-propagated QIV                                                                          In the study among controls: 100% TIV; 22% adjuvanted TIV; 1% unknown whether adjuvanted
                                                                                                                                                                                                                                                                                                            5% TIV; 2% adjuvanted TIV; 53% QIV; 1% LAIV4; 0% cell-propagated QIV (one person vaccinated among controls), 38% unknown                                                                                                                                                                                                                                                                                                                                                           

  Variables of adjustment                              Age group, sex, presence of chronic conditions, calendar time as month (Oct-Jan)                                           Age (modelled as RCS or age group depending on analysis), sex, presence of chronic conditions, onset date (RCS), region   Age (modelled as RCS, age group or linear term depending on analysis), sex, presence of any chronic condition associated with influenza vaccination recommendation, onset date (RCS) and study site   Age group, sex, month of onset, surveillance scheme, risk group                                                                                   Age group, sex, presence of chronic conditions, calendar time as month (Oct-Jan)                                           Age (modelled as RCS or linear term depending on analysis), sex, presence of any chronic condition associated with influenza vaccination recommendation, onset date (RCS or onset month depending on analysis) and study site
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARI: acute respiratory infection; DK-H: Denmark hospital study; DK-PC: Denmark primary care study; ES-PC: Spain primary care study; EU: European Union; EU-H: EU hospital multicentre I-MOVE study; EU-PC: EU primary care multicentre I-MOVE study; GP: general practitioner; ILI: influenza-like illness; I-MOVE: Influenza -- Monitoring Vaccine Effectiveness in Europe; LAIV4: quadrivalent live attenuated influenza vaccine; LRI: lower respiratory infection; QIV: quadrivalent inactivated influenza vaccine; RCS: restricted cubic spline; SARI: severe acute respiratory infection; TIV: trivalent inactivated influenza vaccine; TND: test-negative design; UK-PC: United Kingdom primary care study.

^a^ 235 of 813 sentinel physicians included in ES-PC were also included in EU-PC.

^b^ Patients \< 6 months should have been excluded from the study, however the age group is specified as 'all ages' as age in months could not be verified from the data.

^c^ EU ILI: Sudden onset of symptoms AND at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia AND at least one of the following three respiratory symptoms: cough, sore throat, shortness of breath.

^d^ EU SARI: Hospitalised person with one or more of: fever/feverishness, malaise, headache, myalgia, deterioration of general condition (asthenia, weight loss, anorexia, confusion/dizziness) AND one or more respiratory symptom (cough, sore throat or shortness of breath) at admission or within 48 hours.

^e^ Vaccines were prepared from egg-propagated vaccine viruses, non-adjuvanted and administered intramuscularly unless otherwise specified.

^f^ Where indicated, vaccine coverage among controls were used as representative of the source population from which the cases arose.

^g^ UK vaccine strategy: 2--17 years of age: LAIV4 or QIV; 18--64 years of age: QIV or cell-propagated QIV; ≥ 65  years of age: adjuvanted TIV or cell-propagated QIV.

Vaccinated patients were defined as those having had the 2019/20 influenza vaccine at least 14 days before onset of symptoms (15 days for two studies: EU-PC and EU-H). Those vaccinated less than 14 days (less than 15 days for two studies) before symptom onset, or with unknown date of vaccination were excluded.

Most study countries (six from EU-PC and Denmark) selected all or a random sample of influenza virus-positive specimens for haemagglutinin genome segment and/or whole genome sequencing. This was followed by phylogenetic analysis to determine clade distribution for potential impact on VE. In Spain, the ES-PC study (regions not included in EU-PC) sequenced an ad hoc sample of influenza viruses. In UK-PC, sequencing is done by two contributing surveillance schemes. One of these sequences all influenza viruses with sufficient genetic material (Ct value \< 31) and all viruses derived from vaccinated cases. The other one sequences a subset only. Sequencing results were provided for both studies in Denmark together (DK-PC and DK-H).

Ethical statement
-----------------

The planning, conduct and reporting of the studies was in line with the Declaration of Helsinki \[[@r12]\]. Official ethical approval and patient consent was not required for DK-H and DK-PC according to Danish regulations, nor for EU-PC (the Netherlands and Spain) and UK-PC, as these studies were classified as being part of routine care/surveillance. Other study sites obtained local ethical approval from a national review board, according to local site regulations, as follows: EU-H (Aragon: approved 20 November 2019 by the CEIC Aragon, no registration number given; Granada: approved 11 October 2019 by the CEIM/CEI Provincial de Granada, no registration number given; Navarra: 2018/95; Romania: CE353/30.09.2019); EU-PC (France: 471393; Germany: EA2/126/11; Ireland: ICGP2019.4.04; Portugal: approved 18 January 2012 by the Ethics Committee of Instituto Nacional de Saúde Doutor Ricardo Jorge, no registration number given; Romania: CE354/30.09.2019; Sweden: 2006/1040--31/2).

Statistical analysis
--------------------

Each study computed VE by subtracting the ratio of the odds of vaccination in cases and controls from one, as a percentage (VE = (1 -- odds ratio (OR) x 100%). All studies applied logistic regression to adjust their VE for measured confounding variables ([Table 1](#t1){ref-type="table"}). Study-specific VE was estimated overall and where possible, by age group and target population (as defined locally in the various studies and study sites) against influenza A overall, A(H1N1)pdm09, A(H3N2), influenza B and B/Victoria. For analyses with a small sample size, defined as those having fewer than 10 cases or controls per parameter, a sensitivity analysis was performed using Firth's method of penalised logistic regression (PLR) to assess small sample bias \[[@r13],[@r14]\]. We considered a difference of \> 10% between the PLR and original estimate to be an indication of small sample bias, and any such estimates were not included.

Results
=======

From 30 September 2019 to 29 January 2020, in the primary care setting, there were 12,842 patients included in the DK-PC study (1,723 cases), 1,798 in ES-PC (955 cases), 2,987 in EU-PC (1,052 cases) and 2,548 in UK-PC (782 cases). In the hospital setting, there were 10,761 in DK-H (659 cases) and 601 in EU-H (129 cases).

Overall, 84% (4,466/5,310) of confirmed infections were influenza A virus-positive and 16% (844/5,310) were influenza B virus-positive, noting that the previously mentioned total refers to patients rather than infections. The proportion of subtyped influenza A viruses was 93% to 98% in EU-H, ES-PC, EU-PC and UK-PC, and 45% to 51% in DK-H/DK-PC. Most subtyped influenza A viruses were influenza A(H1N1)pdm09 (67--89%) in ES-PC, EU-PC and EU-H; this subtype comprised 46% to 47% in DK-PC/DK-H and 7% in UK-PC ([Figure 2](#f2){ref-type="fig"}). The proportion of influenza B viruses ranged from 4% in UK-PC to 30% in ES-PC ([Figure 2](#f2){ref-type="fig"}). The proportion of B viruses ascribed to a lineage was 27% overall (100% for EU-H, 70% for EU-PC, 23% for UK; lineage information not available in DK-PC, DK-H and ES-PC studies). Most of those that were ascribed to a lineage were B/Victoria: 98% in EU-PC, 75% in UK and 67% in EU-H.

![Proportion of influenza virus (sub)types among cases, six European studies, interim influenza season 2019/20 (n = 5,310)](2000153-f2){#f2}

All influenza (A and B)
-----------------------

### Primary care settings

For all ages, VE against laboratory-confirmed influenza (both A and B combined) ranged from 29% (95% confidence interval (CI): 4 to 48) in UK-PC to 61% (95% CI: 37 to 76) in ES-PC. The VE against all influenza among children aged 0 to 17 years was 64% (95% CI: 16 to 85) in EU-PC and 95% (95% CI: 67 to 99) in DK-PC. For those aged 0 to 14 years in ES-PC, VE was 67% (95% CI: 18 to 87), while for those aged 2 to 17 years in UK-PC, VE was 37% (95% CI: −21 to 67). For patients aged 18 to 64 years, VE ranged from 36% (95% CI: 1 to 58) in UK-PC to 58% (95% CI: 43 to 69) in DK-PC. For those aged 15 to 64 years in ES-PC, VE was 55% (95% CI: 10 to 77) ([Table 2](#t2){ref-type="table"}). In ES-PC and EU-PC target groups for influenza vaccination, VE was 60% (95% CI: 22 to 79) and 53% (95% CI: 26 to 70), respectively.

###### Interim vaccine effectiveness (VE) against all laboratory-confirmed influenza, influenza A, A(H1N1)pdm09, A(H3N2) and B, by age group, target group for vaccination and by study, six European studies, influenza season 2019/20

  Influenza (sub)type and study   Setting    Study population^a^   Cases   Controls   VE^b^   95% CI                              
  ------------------------------- ---------- --------------------- ------- ---------- ------- -------- ------- ------------ ----- ------------
  **All influenza (A and B)**                                                                                                     
  DK-PC^c^                        PC         All ages              1,715   119        7       11,127   1,349   12           56    46 to 65
  0--17 years                     669        1                     \< 1    3,793      669     18       95      67 to 99           
  18--64 years                    862        48                    6       5,436      480     9        58      43 to 69           
  ≥ 65 years                      184        70                    38      1,898      808     43       40      18 to 57           
  ES-PC                           PC         All ages              955     46         5       843      79      9            61    37 to 76
  0--14 years                     416        14                    3       298        15      5        67      18 to 87           
  15--64 years                    513        19                    4       473        27      6        55      10 to 77           
  Target group^d^                 105        27                    26      181        57      31       60      22 to 79           
  EU-PC                           PC         All ages              1,052   76         7       1,935    211     11           53    34 to 67
  0--17 years                     419        12                    3       810        28      4        64      16 to 85           
  18--64 years                    566        33                    6       920        81      9        51      21 to 70           
  Target group^d^                 197        52                    26      509        158     31       53      26 to 70           
  UK-PC                           PC         All ages              782     114        15      1,766    308     17           29    4 to 48
  2--17 years                     303        24                    8       358        28      8        37      −21 to 67          
  18--64 years                    379        44                    12      937        119     13       36      1 to 58            
  ≥ 65 years                      72         46                    64      281        161     57       26      −44 to 62          
  DK-H^c^                         H          All ages              658     168        26      10,103   2,745   27           40    27 to 51
  18--64 years                    237        30                    13      3,397      533     16       48      22 to 65           
  ≥ 65 years                      315        134                   43      5,008      2,166   43       35      17 to 49           
  EU-H^c^                         H          ≥ 65 years            128     54         42      473      312     66           60    39 to 74
  **Influenza A**                                                                                                                 
  DK-PC                           PC         All ages              1,540   115        8       11,127   1,349   12           54    43 to 63
  0--17 years                     579        1                     \< 1    3,793      61      2        95      63 to 99           
  18--64 years                    786        47                    6       5,436      480     9        54      38 to 67           
  ≥ 65 years                      175        67                    38      1,898      808     43       41      18 to 57           
  ES-PC                           PC         All ages              670     40         6       843      79      9            60    34 to 76
  0--14 years                     244        12                    5       298        15      5        48      −39 to 81          
  15--64 years                    400        15                    4       473        27      6        62      20 to 82           
  Target group^d^                 90         23                    26      181        57      31       62      24 to 82           
  EU-PC                           PC         All ages              746     67         9       1,906    210     11           53    32 to 67
  0--17 years                     261        10                    4       800        28      4        53      −19 to 81          
  18--64 years                    426        27                    6       903        81      9        60      32 to 76           
  Target group^d^                 161        46                    29      503        157     31       49      16 to 69           
  UK-PC                           PC         All ages              756     110        15      1,766    308     17           30    4 to 49
  2--17 years                     294        23                    8       358        28      8        39      −19 to 69          
  18--64 years                    364        42                    12      937        119     13       38      3 to 60            
  ≥ 65 years                      70         45                    64      281        161     57       24      −49 to 61          
  DK-H                            Hospital   All ages              629     162        26      10,103   2,745   27           41    27 to 52
  18--64 years                    226        29                    13      3,397      533     16       47      21 to 65           
  ≥ 65 years                      306        129                   42      5,008      2,166   43       37      19 to 50           
  EU-H^c^                         Hospital   ≥ 65 years            122     50         41      473      312     66           62    41 to 76
  **Influenza A(H1N1)pdm09**                                                                                                      
  DK-PC                           PC         All ages              373     14         4       11,127   1,349   12           75    57 to 86
  18--64 years                    229        10                    4       5,436      480     9        67      38 to 83           
  ≥ 65 years                      28         4                     NC      1,898      808     43       79      37 to 93           
  ES-PC                           PC         All ages              566     30         5       843      79      9            69    46 to 82
  0--14 years                     198        10                    5       298        15      5        51      −45 to 83          
  15--64 years                    349        12                    3       473        27      6        68      28 to 86           
  Target group^d^                 76         17                    22      181        57      31       73      40 to 88           
  EU-PC                           PC         All ages              487     33         7       1,906    210     11           48    18 to 68
  0--17 years                     172        9                     5       786        27      3        46      −51 to 80          
  18--64 years                    292        14                    5       903        81      9        49      1 to 74            
  DK-H                            Hospital   All ages              132     22         17      10,103   2,745   27           54    24 to 72
  18--64 years                    68         8                     12      3,397      533     16       55      3 to 79            
  ≥ 65 years                      44         12                    NC      5,008      2,166   43       51      4 to 75            
  EU-H^c^                         Hospital   ≥ 65 years            98      42         43      445      303     68           63    40 to 77
  **Influenza A(H3N2)**                                                                                                           
  DK-PC                           PC         All ages              418     45         11      11,127   1,349   12           27    −4 to 49
  18--64 years                    190        17                    9       5,436      480     9        29      −19 to 57          
  ≥ 65 years                      55         27                    NC      1,898      808     43       12      −53 to 49          
  ES-PC                           PC         All ages              75      10         13      799      79      10           −58   −338 to 43
  EU-PC                           PC         All ages              244     33         14      1,772    180     10           57    27 to 75
  18--64 years                    125        12                    10      834        75      9        71      37 to 87           
  Target group^d^                 70         28                    40      431        126     29       38      −21 to 69          
  UK-PC                           PC         All ages              675     103        15      1,766    308     17           25    −3 to 46
  2--17 years                     273        22                    8       358        28      8        39      −21 to 69          
  18--64 years                    308        38                    12      937        119     13       31      −8 to 56           
  ≥ 65 years                      66         43                    65      281        161     57       21      −56 to 60          
  DK-H                            Hospital   All ages              154     59         38      10,103   2,745   27           −13   −58 to 19
  ≥ 65 years                      89         53                    60      5,008      2,166   43       −16     −80 to 25          
  EU-H^c^                         Hospital   ≥ 65 years            12      4          NC      313      199     64           60    −69 to 90
  **Influenza B**                                                                                                                 
  DK-PC                           PC         All ages              183     4          2       11,127   1,349   12           83    51 to 94
  ES-PC                           PC         All ages              285     6          2       843      79      9            66    7 to 87
  EU-PC                           PC         All ages              305     9          3       1,373    169     12           62    17 to 83
  18--64 years                    138        6                     4       658        64      10       12      −135 to 67         
  **Influenza B Victoria**                                                                                                        
  EU-PC^c^                        PC         All ages              209     5          2       1,190    141     12           60    −12 to 86

CI: confidence interval; DK-PC: Denmark primary care study; DK-H: Denmark hospital study; ES-PC: Spain primary care study; EU-H: European Union hospital multicentre I-MOVE study; EU-PC: European Union primary care multicentre I-MOVE study; I-MOVE: Influenza - Monitoring Vaccine Effectiveness in Europe; LAIV4: quadrivalent live attenuated influenza vaccine; NC: not calculated (percentages not shown where denominators \< 60); PC: primary care; UK-PC: United Kingdom primary care study; Vacc: vaccinated; VE: vaccine effectiveness.

Countries included in EU-H analysis for any influenza, influenza A and influenza A(H3N2): Romania and Spain. For analysis against influenza A(H1N1)pdm09: Spain only.

Countries included in EU-PC analysis for all influenza, influenza A and A(H1N1)pdm09: France, Germany, Ireland, the Netherlands, Portugal, Romania, Spain and Sweden. For analysis against influenza A(H3N2): France, Germany, Ireland, the Netherlands, Romania, Spain and Sweden are included. For analysis against influenza B: France, Germany, Ireland, Portugal, Romania, Spain and Sweden. For analysis against influenza B/Victoria: France, Germany, Ireland, Portugal, Romania and Sweden.

^a^ Age-specific or target group-specific VE was not included for overall or (sub)type-specific VE in some study sites, where sample size did not allow estimation of VE.

^b^ For details of adjustment variables, see [Table 1](#t1){ref-type="table"}.

^c^ Some records with missing values were dropped from this analysis.

^d^ Groups targeted by seasonal influenza vaccination as defined locally in the studies and study sites.

### Hospital settings

For all ages, VE against all laboratory-confirmed hospitalised influenza was 40% in DK-H (95% CI: 27 to 51). In older adults (aged at least 65 years), VE was 35% (95% CI: 17 to 49) in DK-H and 60% (95% CI: 39 to 74) in EU-H.

Influenza A overall
-------------------

### Primary care settings

The VE against laboratory-confirmed influenza A for all ages ranged from 30% (95% CI: 4 to 49) in UK-PC to 60% (95% CI: 34 to 76) in ES-PC. The VE against influenza A among adults under 65 years ranged from 38% (95% CI: 3 to 60) in UK-PC (18--64-year-olds) to 62% (95% CI: 20 to 82) in the ES-PC study (15--64-year-olds). In children less than 18 years of age, the VE ranged from 39% (95% CI: -19 to 69) in UK-PC (2--17-year-olds) to 95% (95% CI: 63 to 99) in DK-PC (0--17-year-olds) ([Table 2](#t2){ref-type="table"}).The VE in EU-PC and ES-PC target groups for influenza vaccination was 49% (95% CI: 16 to 69) and 62% (95% CI: 24 to 82), respectively.

### Hospital settings

For all ages, VE against laboratory-confirmed hospitalised influenza A was 41% (95% CI: 27 to 52) in DK-H. For older adults, VE was 37% (95% CI: 19 to 50) in DK-H and 62% (95% CI: 41 to 76) in EU-H.

Influenza A(H1N1)pdm09
----------------------

### Primary care settings

For all ages, VE against laboratory-confirmed influenza A(H1N1)pdm09 ranged between 48% (95% CI: 18 to 68) in EU-PC and 75% (95% CI: 57 to 86) in DK-PC. The number of vaccinated cases in the UK-PC study was too small to provide a VE estimate.

The VE among children less than 18 years of age was 46% (95% CI: −51 to 80) in EU-PC (0--17 years) and 51% (95% CI −45 to 83) in ES-PC (0--14 years). Among adults less than 65 years, VE was between 49% (95% CI: 1 to 74) in EU-PC (18--64 years) and 68% (95% CI: 28 to 86) in ES-PC (15--64 years). VE for adults aged 65 years and older was 79% (95% CI: 37 to 93) in the DK-PC study. Target groups in the ES-PC had VE of 73% (95% CI: 40 to 88) against influenza A(H1N1)pdm09.

### Hospital settings

For hospitalised patients aged 65 years and older, VE was 51% (95% CI: 4 to 75) in DK-H and 63% (95% CI: 40 to 77) in the EU-H study ([Table 2](#t2){ref-type="table"}). For hospitalised patients in DK-H aged 18 to 64 years, VE was 55% (95% CI: 3 to 79).

### Virological results

Among the 212 A(H1N1)pdm09 viruses sequenced, 90% (n = 190) belonged to genetic clade 6B.1A5A ([Table 3](#t3){ref-type="table"}) and none belonged to the same clade as the vaccine component (6B.1A1). Twenty viruses (9%) belonged to the 6B.1A5B clade and one virus (1%) each to the 6B.1A6 and 6B.1A7 clades.

###### Influenza viruses characterised by clade, amino acid substitutions and study site, five European studies, interim influenza season 2019/20 (n = 605)

  Influenza virus                        Clade               DK-H/DK-PC^a^   ES-PC^b^       EU-PC^c,d^    UK-PC^d^                      
  -------------------------------------- ------------------- --------------- -------------- ------------- ---------- ---- ------- ----- ----
  **Total influenza A(H1N1)pdm09**       **n = 505**         **n  = 566**    **n  = 496**   **n = 50**                                  
  **Sequenced**                          **72**              15              **86**         15            **46**     9    **8**   16    
  A/Norway/3433/2018-like                6B.1A5A             56              78             84            98         43   NC      7     NC
  A/Switzerland/3330/2017-like           6B.1A5B             15              21             2             2          3    NC      0     NC
  A/Slovenia/1489/2019-like              6B.1A7              1               1              0             0          0    NC      0     NC
  A/Brisbane/02/2018-like                6B.1A1              0               0              0             0          0    NC      0     NC
  A/Ireland/84630/2018-like              6B.1A6              0               0              0             0          0    NC      1     NC
  **Total influenza A(H3N2)**            **n = 572**         **n  = 75**     **n  = 250**   **n = 675**                                 
  **Sequenced**                          68                  12              23             31            75         30   168     25    
  A/South Australia/34/2019-like         3C.2a1b + T131K     27              40             6             NC         21   28      13    8
  A/La Rioja/2202/2018-like              3C.2a1b + T135K-A   1               1              9             NC         10   13      1     1
  A/Hong Kong/2675/2019-like             3C.2a1b + T135K-B   9               13             1             NC         1    1       4     2
  A/Kansas/14/2017-like                  3C.3a               31              46             7             NC         43   57      150   89
  **Total influenza B**                  **n = 213**         **n = 285**     **n = 317**    **n = 8**                                   
  **Sequenced^e^**                       8                   4               0              0             46         15   5       63    
  **Total B/Victoria among sequenced**   8                   NC              0              NC            46         NC   5       NC    
  B/Colorado/06/2017-like                1A (del162--163)    0               NC             0             NC         1    NC      0     NC
  B/Hong Kong/269/201-like               1A (del162--164)A   0               NC             0             NC         0    NC      0     NC
  B/Washington/02/2019-like              1A (del162--164)B   8               NC             0             NC         45   NC      5     NC

DK-PC: Denmark primary care study; DK-H: Denmark hospital study; ES-PC: Spain primary care study; EU-PC: European Union primary care multicentre I-MOVE study; I-MOVE: Influenza -- Monitoring Vaccine Effectiveness in Europe; NC: not calculated (percentages not shown where denominators \< 60); UK-PC: United Kingdom primary care study.

^a^ DK-H and DK-PC samples are combined; sequence information is based on influenza-positive samples received for surveillance at the National Influenza Center Denmark from week 40/2019 and 4/2020.

^b^ Specimens sequenced from Spain originate from the entire National Influenza Surveillance System in weeks 40/2019 to 4/2020.

^c^ Two specimens from ES-PC also included in EU-PC data.

^d^ At time of publishing not all specimens from the study period were processed.

^e^ No B/Yamagata samples had been sequenced at the time of publishing.

Influenza A(H3N2)
-----------------

### Primary care settings

For patients of all ages, VE against influenza A(H3N2) ranged from −58% (95% CI: −338 to 43) in ES-PC to 57% (95% CI: 27 to 75) in EU-PC. For children aged 2 to 17 years in the UK-PC, VE was 39% (95% CI: −21 to 69). For those aged 18 to 64 years, VE was between 29% (95% CI: −19 to 57) in DK-PC and 71% (95% CI: 37 to 87) in EU-PC. VE ranged from 12% (95% CI: −53 to 49) in DK-PC to 21% (95% CI: −56 to 60) in UK-PC in those aged 65 years and over. For target groups in the EU-PC, VE against influenza A(H3N2) was 38% (95% CI: −21 to 69) ([Table 2](#t2){ref-type="table"}).

### Hospital settings

VE among hospitalised patients aged 65 years and older against influenza A(H3N2) was between −16% (95% CI: −80 to 25) in DK-H and 60% (95% CI: −69 to 90) in EU-H ([Table 2](#t2){ref-type="table"}).

### Virological results

Of the 334 influenza A(H3N2) viruses sequenced, 69% (n = 231) belonged to the same genetic clade as the vaccine strain (3C.3a), 20% (n = 67) belonged to 3C.2a1b + T131K, 6% to 3C.2a1b + T135K-A (n = 21) and 5% to 3C.2a1b + T135K-B (n = 15). The distribution of (sub)clades varied by country, e.g. from 46% (n = 31) in DK-H/DK-PC to 89% (n = 150) in UK-PC for clade 3C.3a, and with only 23 of 75 A(H3N2) viruses sequenced overall in ES-PC.

Influenza B
-----------

### Primary care settings

Sample sizes for influenza B were large enough to estimate VE in three studies in the primary care setting only (DK-PC, ES-PC and EU-PC). The VE against laboratory-confirmed influenza B for all age groups ranged from 62% (95% CI: 17 to 83) in EU-PC to 83% (95% CI: 51 to 94) in DK-PC. For those aged 18--64 years, VE was 12% in EU-PC (95% CI: −135 to 67) ([Table 2](#t2){ref-type="table"}). VE against B/Victoria was 60% (95% CI: −12 to 86) (only estimated for EU-PC). The number of cases of B/Yamagata was too low for VE to be estimated.

### Virological results

Of the 59 influenza B/Victoria viruses sequenced, 58 belonged to subgroup 1A(del162--164)B and one belonged to the vaccine subclade 1A(del162--163).

Sensitivity analyses
--------------------

Results with small sample sizes were subject to sensitivity analyses, all of which gave similar results (absolute difference range: 1--6%).

Discussion
==========

Our results for the 2019/20 influenza season in six well-known influenza studies across Europe indicate that interim VE against any laboratory-confirmed influenza among all ages in primary care and hospital settings ranged between 29% and 61%, while VE was from 53% to 60% in vaccination target groups. The proportions of influenza (sub)types contributing to these overall results varied considerably by study.

Against influenza A (all subtypes) among all ages, point estimates for VE ranged between 30% and 60% in both types of settings, and they were slightly higher (49--62%) in the target groups for vaccination. Against influenza A(H1N1)pdm09, VE point estimates among all ages ranged from 48% to 75%, being slightly higher among older adults (aged 65 years and older) in DK-PC at 79% and slightly lower in children aged 0 to 17 years in EU-PC (46%). There were varied results for VE against influenza A(H3N2). For patients of all ages combined, two studies (one primary care, one hospital) had VE point estimates \< 0%, two (primary care) had VE \< 30%, and two (one primary care, one hospital) had VE \> 50%. The VE point estimate against A(H3N2) was highest among 18 to 64-year-olds in EU-PC (71%). Against laboratory-confirmed influenza B, VE among all ages ranged from 62% to 83% in primary care settings.

The VE point estimates against all influenza from three of four primary care studies (DK-PC, ES-PC and EU-PC) over all ages, at 53% to 61%, are similar to VE point estimates from Canada (58%) \[[@r15]\], and a little higher than those reported from the United States (US) (45%) \[[@r16]\], noting that proportions of influenza (sub)types and proportions of study participants contributing to age groups may be slightly different across all studies. For older adults (aged 65 years and over), the six studies presented here had VE point estimates of 43% to 66% across all settings. This is similar to estimates from Finland, Sweden and Canada for this age group, at 41% \[[@r17]\], 44% \[[@r18]\] and 60% \[[@r15]\], respectively. It is also similar for those aged 50 years and over in the US, at 43% \[[@r16]\], noting that underlying proportions of influenza (sub)types are likely to be different across all studies.

The 2019/20 interim VE against influenza A(H1N1)pdm09 was higher compared with the 2018/19 interim season estimates in most studies among all ages, except for the EU-PC study \[[@r19]\]. The VE against A(H1N1)pdm09 was also higher among those aged 65 years and older in the hospital-based studies in the 2019/20 season compared with the previous season \[[@r19]\]. The main circulating genetic clade in the 2019/20 studies is 6B.1A5A and to a lesser extent, 6B.1A5B, which although different from the vaccine strain, show good reactivity with ferret antiserum raised against the vaccine virus \[[@r20]\]. The 2019/20 interim influenza A(H1N1)pdm09 VE in Canada \[[@r15]\] and the US \[[@r16]\] was 44% and 37%, respectively. These overall results are lower than the DK-PC and ES-PC results, but are more comparable with the EU-PC results (48%). In the US, there was some indication of lower VE among younger adults (18--49 years) with VE being 5% \[[@r16]\]. None of the studies reported in this article indicate a much lower A(H1N1)pdm09 VE among younger adults. End-of-season overall results as well as clade/genetic variant-specific results and birth cohort-specific VE will help understand differences between studies at international level.

Unlike observed estimates in the 2018/19 season, in which three of five studies reporting A(H3N2) cases had VE below zero and all were below 50% \[[@r19]\], two of six 2019/20 interim study results were below zero, two were between 25% and 50%, and two were between 50% and 60%. The EU-PC and the ES-PC studies showed very different point estimates of A(H3N2) VE among all ages; however, there were only eight cases in common across these studies. There is considerable variation in the VE estimates against A(H3N2) presented here, which may go hand-in-hand with the considerable genetic diversity observed. While A(H3N2) viruses remain difficult to characterise antigenically \[[@r20]\], reports suggest that the 3C.3a circulating viruses were antigenically similar to the vaccine virus. While a higher VE against A(H3N2) among studies with high proportions of 3C.3a characterised viruses might be anticipated, this was not observed everywhere. The other viruses circulating belonged to the 3C.2a1b clade, most with additional substitutions. These viruses are more genetically distinct from the vaccine virus and therefore antigenically less similar. However, 2019/20 interim VE from Canada against A(H3N2) was 62%, and 94% of the 80 viruses sequenced in Canada belonged to the 3C.2a1b clade. While clade-specific VE estimates at the end of the 2019/20 season could elucidate whether different circulating clades of A(H3N2) viruses across the region explain the differences in VE against A(H3N2) observed here in these studies, some of the observed differences in interim VE may indicate that further explanations, such as immunological cohort effects \[[@r21]\], need to be investigated.

Recent vaccine seed A(H3N2) viruses have developed adaptions during propagation in eggs, potentially negatively affecting VE \[[@r22]\]. Cell-propagated vaccines were used in some studies, but there was insufficient data to estimate vaccine type-specific VE.

VE against influenza B was \> 60% among all ages in primary care, with a lower VE among those aged 18 to 64 years in EU-PC. However, sample size was lower in this age group and the low VE may possibly be a result of random variation. The high overall VE was comparable with 2019/20 interim VE against influenza B in Canada (69%) \[[@r15]\]. In the US, overall VE against B/Victoria was lower, at 50% \[[@r16]\].

In studies where lineage was available, the vast majority of circulating influenza B belonged to the B/Victoria lineage, which was the lineage included in the trivalent vaccine but of another subgroup. The quadrivalent vaccine was used widely in Europe, however because of low circulation of B/Yamagata viruses, the VE of quadrivalent and trivalent vaccines could not be compared in the context of VE against trivalent lineage-mismatched influenza B. Among the sequenced B/Victoria viruses, 98% belonged to the subgroup 1A(del162--164)B, differing from the vaccine virus by a further amino acid deletion, and being antigenically different \[[@r3],[@r23],[@r24]\]. Nevertheless, human serology studies show some evidence of cross-reactivity between the vaccine and the circulating B/Victoria viruses \[[@r20],[@r23],[@r24]\].

The early start of the season in most European countries included in these six studies \[[@r5]\] resulted in higher incidence and greater precision for interim VE estimates than in 2018/19, although some studies did have lower sample size for some subgroups in this interim analysis. Each study used study-specific criteria to define if a sample size was too small to attempt to estimate VE. Where VE results were presented, and sample size was small, sensitivity analyses were used to address potential small sample bias where appropriate. End-of-season estimates will have higher sample size and provide more robust estimates. Residual confounding and bias are known limitations potentially present in all observational studies.

Vaccination remains the key successful method of influenza prevention, with one to two-thirds of all vaccinated individuals receiving protection during the 2019/20 influenza season. Promotion of influenza vaccination should be maintainted in line with national guidelines and recommendations in all European countries with ongoing influenza virus circulation. Given the variation in VE estimates against A(H3N2), it remains important that when national guidelines indicate neuraminidase inhibitors to be used, they are used regardless of vaccination status as prophylaxis and therapy where there is influenza A(H3N2) virus circulation to help prevent severe outcomes \[[@r1]\].

Bi-annual reports on influenza VE in prior and existing seasons are provided by the Global Influenza VE (GIVE) Collaboration. The February 2020 GIVE report included interim VE results presented here to help inform the WHO Vaccine Strain Selection Committee meeting of 24 to 27 February 2020 in Geneva. For the 2020/21 northern hemisphere season, WHO provided specific recommendations for egg-based, cell-based and recombinant-based vaccines \[[@r25]\]. Compared with the northern hemisphere 2019/20 trivalent vaccine recommendations, all components for the 2020/21 trivalent vaccine have been changed. For influenza A(H1N1)pdm09, WHO recommended A/Guangdong-Maonan/SWL1536/2019(H1N1)pdm09-like virus for egg-based vaccines and A/Hawaii/70/2019 (H1N1)pdm09-like virus for cell-based or recombinant-based vaccines, which are 6B.1A5A viruses, harbouring additional D187A and Q189E substitutions. For influenza A(H3N2), WHO recommended A/HongKong/2671/2019 (H3N2)-like virus for egg-based vaccines and A/HongKong/45/2019 (H3N2)-like virus for cell-based or recombinant-based vaccines, both 3C.2a1b + T135K-B viruses, harbouring S137F, A138S and F193SHA substitutions. For the 2020 southern hemisphere influenza vaccine, WHO recommended for both 2020/21 northern hemisphere trivalent and quadrivalent vaccines a B/Washington/02/2019-like (B/Victoria lineage) virus (a three amino acid deletion virus), and additionally, a B/Phuket/3073/2013-like (B/Yamagata lineage) virus for the quadrivalent vaccine \[[@r25]\].

The VE and antigenic studies at the end of the 2019/20 season will help to explain the differences in age-, subtype- and study-specific VE estimates presented here. In order to be prepared for the next season in the northern hemisphere, we should continue to monitor the genetic diversity of the 2020 southern hemisphere influenza viruses and their influenza VE.
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